Ishan Capila
YOU?
Author Swipe
View article: Optimizing Antibody Affinity and Developability Using a Framework–CDR Shuffling Approach—Application to an Anti-SARS-CoV-2 Antibody
Optimizing Antibody Affinity and Developability Using a Framework–CDR Shuffling Approach—Application to an Anti-SARS-CoV-2 Antibody Open
The computational methods used for engineering antibodies for clinical development have undergone a transformation from three-dimensional structure-guided approaches to artificial-intelligence- and machine-learning-based approaches that le…
View article: Variable blood processing procedures contribute to plasma proteomic variability
Variable blood processing procedures contribute to plasma proteomic variability Open
Background Plasma is a potentially rich source of protein biomarkers for disease progression and drug response. Large multi-center studies are often carried out to increase the number of samples analyzed in a given study. This may increase…
View article: Additional file 3 of Variable blood processing procedures contribute to plasma proteomic variability
Additional file 3 of Variable blood processing procedures contribute to plasma proteomic variability Open
Additional file 2: Tables S11–S16.
View article: Additional file 2 of Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?
Additional file 2 of Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis? Open
Additional file 2. Tables S1-S8.
View article: Additional file 2 of Variable blood processing procedures contribute to plasma proteomic variability
Additional file 2 of Variable blood processing procedures contribute to plasma proteomic variability Open
Additional file 3: Tables S7–S10.
Enhancing reproducibility of gene expression analysis with known protein functional relationships: The concept of well-associated protein Open
Identification of differentially expressed genes (DEGs) is well recognized to be variable across independent replications of genome-wide transcriptional studies. These are often employed to characterize disease state early in the process o…
View article: Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease
Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease Open
Background: The sequelae of Kawasaki disease (KD) vary widely with the greatest risk for future cardiovascular events among those who develop giant coronary artery aneurysms (CAA). We sought to define the molecular signature associated wit…
View article: MOESM2 of Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor
MOESM2 of Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor Open
Additional file 2: Tables S3-S6.
View article: Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics
Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics Open
The characterization of glycosylation is required for many protein therapeutics. The emergence of antibody and antibody-like molecules with multiple glycan attachment sites has rendered glycan analysis increasingly more complicated. Relian…
View article: Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis Open
The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies (DMTs) have been approved by the US Food and Drug Administration (FDA) for the treat…
View article: Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate Open
In summary, this comprehensive approach across different biological and immunological pathways modulated by glatiramer acetate consistently supported the biological and immunological equivalence of Glatopa and Copaxone.
View article: An integrated approach using orthogonal analytical techniques to characterize heparan sulfate structure
An integrated approach using orthogonal analytical techniques to characterize heparan sulfate structure Open
Heparan sulfate (HS), a glycosaminoglycan present on the surface of cells, has been postulated to have important roles in driving both normal and pathological physiologies. The chemical structure and sulfation pattern (domain structure) of…
View article: Combining measurements to estimate properties and characterization extent of complex biochemical mixtures; applications to Heparan Sulfate
Combining measurements to estimate properties and characterization extent of complex biochemical mixtures; applications to Heparan Sulfate Open
Complex mixtures of molecular species, such as glycoproteins and glycosaminoglycans, have important biological and therapeutic functions. Characterization of these mixtures with analytical chemistry measurements is an important step when d…
View article: Gene expression levels in Th2-polarized cells exposed to Glatopa vs Copaxone.
Gene expression levels in Th2-polarized cells exposed to Glatopa vs Copaxone. Open
Th, T-helper.*P-values are from Student’s t-tests comparing the mean expression of Glatopa with that of Copaxone.†Log2 of the fold difference in mean expression for Glatopa compared with Copaxone.Gene expression levels in Th2-polarized cel…
View article: Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)
Demonstration of equivalence of a generic glatiramer acetate (Glatopa™) Open
Glatiramer acetate (GA) has been available under the brand name Copaxone® for nearly two decades. Recently, the US Food and Drug Administration (FDA) approved the first generic GA, Glatopa™, as fully substitutable for all indications for w…
View article: Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone® Open
Glatopa™ is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone®. Micro…
View article: Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis
Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis Open
Host cell protein (HCP) impurities are generated by the host organism during the production of therapeutic recombinant proteins, and are difficult to remove completely. Though commonly present in small quantities, if levels are not control…